AMIODARONE 150 MG/3 ML VIAL

What it is

AMIODARONE 150 MG/3 ML VIAL is how the CMS NADAC file names this product. The FDA NDC Directory lists it as amiodarone hydrochloride.

FDA gives its dosage form as injection, solution and its route as intravenous.

Its labelers, the companies named on the label, are Hikma Pharmaceuticals USA Inc. and Fresenius Kabi USA, LLC.

FDA’s Established Pharmacologic Class for it is Antiarrhythmic.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $1.56 for 3 mL (3 × $0.52115 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-07-22. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.

The NADAC of all 2 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-07-22. The file is new; the price is not.

What NADAC measures · NADAC explanation codes · Carried-forward prices

All 2 NDCs

• 00143-9875-25 · Hikma Pharmaceuticals USA Inc. · $0.52115 per ML · eff. 2026-07-22 filed carried forward
• 63323-0616-03 · Fresenius Kabi USA, LLC · $0.52115 per ML · eff. 2026-07-22 filed carried forward

Other strengths, forms and brands

5 other products in the NADAC file share the FDA nonproprietary name amiodarone hydrochloride with AMIODARONE 150 MG/3 ML VIAL.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. between 2025-11-19 and 2026-09-23 (4 dates) · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $0.52115 per ML filed.

Of the 21 other products in FDA’s Antiarrhythmic class priced per ML, 4 have a higher middle NADAC price and 17 a lower one. The one in the middle is LIDOCAINE HCL 4% SOLUTION, at $0.22203 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J0282, for 2026-10-01 to 2026-12-31, comes to $1.92 for 3 mL, or $0.64 per ML once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.0768 per 30 MG.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 3 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 3 mL; your package may hold a different amount.
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.